Osteoporosis how long to treat? /

Get full text
Series

Combination and sequential therapy for the treatment of Osteoporosis

Get full text
Series

Pharmacometric approaches to optimize use of drugs and dialysis treatments in patients with chronic kidney disease

Get full text
Series

Pharmacometrics in tuberculosis

Get full text
Series

Synaptic plasticity in striatal function

Get full text
Series

Promising medical therapies for Parkinson's disease

Get full text
Series

Mechanisms of L-DOPA-induced dyskinesia in Parkinson's disease

Get full text
Series

Management of MDR and XDR TB

Get full text
Series

Tuberculosis new treatments in evolution /

Get full text
Series

Key drug discovery challenges in cardiovascular medicine

Get full text
Series (Genetics of cardiovascular disease)
Series (Small molecule drug discovery)

Targeting Aß oligomers a molecular basis for the cause, diagnosis, and treatment of Alzheimer's disease /

Get full text
Series

Current trends in antiviral drug development

Get full text
Series (Antivirals)
Series (Small molecule drug discovery)

Immune response and rational development of vaccines and biomarkers

Get full text
Series

Current drugs for TB treatment

Get full text
Series

Skin side effects targeted anti-EGFR and anti-BRAF therapies

Get full text

Anti-seizure drugs discovery and development /

Get full text
Series (Epilepsy and seizures)
Series (Drug discovery)

Discovery of schizophrenia drug targets from DISC1 mechanisms

Get full text
Series (Drug discovery and development in the neurosciences)
Series (Small molecule drug discovery).

Discovery of Levetiracetam (Keppra(R)) the first SV2A ligand for the treatment of epilepsy /

Get full text
Series (Drug discovery and development in the neurosciences)
Series (Small molecule drug discovery)

The development of current treatments for tuberculosis

Get full text
Series

Development of new regimens for tuberculosis

Get full text
Series